Troglitazone, a peroxisome proliferator-activated receptor γ ligand, induces growth inhibition and apoptosis of HepG2 human liver cancer cells

Figure 1 Effect of troglitazone on growth of HepG2 cells. Cells were incubated with different concentrations of troglitazone for 120 h. Troglitazone inhibited growth of HepG2 cells in a dose-dependent manner, as demonstrated by MTT assay. Data represent the mean ± SD from six wells. ^bP < 0.01 vs corresponding control group (unpaired Student’s t test).